A Study of Pulmonary Arterial Hypertension Participants Treated With Macitentan or Selexipag

Condition:   Pulmonary Arterial Hypertension Intervention:   Drug: PAH medication Sponsor:   Janssen-Cilag S.p.A. Not yet recruiting

Source: ClinicalTrials.gov - September 28, 2020 Category: Research Source Type: clinical trials